February 20, 2026
In the U.S., most routine quality testing that brands and retailers use to support day‑to‑day sales of ingestible hemp products is not automatically subject to FDA’s Laboratory Accreditation for Analyses of Foods (LAAF) program.
But that doesn’t mean LAAF is irrelevant. In 2024–2025, FDA moved the LAAF program into stepwise implementation for certain import‑related testing situations—exactly the scenarios that tend to occur when products are detained, refused, or placed on an import alert.
This guide explains when LAAF accreditation is mandatory versus optional, how to vet labs (LAAF vs. ISO/IEC 17025), and how to use contracts to protect your supply chain—especially if you sell higher‑risk imported ingestible hemp items.
Focus keyword: FDA LAAF hemp edibles testing
Informational only; not legal advice. Regulations and FDA positions can change—confirm requirements for your products and fact pattern.
The LAAF program is FDA’s FSMA‑mandated laboratory accreditation system for food testing in defined circumstances. The program is established in 21 CFR part 1, subpart R and was finalized in a rule published December 3, 2021 (86 FR 68728; effective February 1, 2022). It creates an FDA‑recognized framework where:
Official FDA overview: https://www.fda.gov/food/food-safety-modernization-act-fsma/laboratory-accreditation-analyses-foods-laaf-program-final-rule
LAAF does not require that all food testing in the market be performed by LAAF labs. It is a targeted tool intended to improve reliability of testing when FDA is making (or re‑making) decisions about food safety issues—particularly in import and enforcement contexts.
In other words: a standard commercial certificate of analysis (COA) used for routine vendor qualification may be helpful for your internal compliance program, but it is not automatically a “LAAF scenario.”
Ingestible hemp products are commonly marketed as foods, beverages, or dietary supplements. Regardless of how the market describes them, FDA may treat an ingestible product as a food under the Federal Food, Drug, and Cosmetic Act depending on composition, claims, intended use, and labeling.
FDA continues to issue enforcement communications about ingestible products that contain certain hemp‑derived ingredients or make impermissible therapeutic claims. For example, FDA warning letters can allege products are adulterated foods due to unsafe food additives (example warning letter, July 16, 2025): https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stnr-creations-llc-698700-07162025
Why that matters for LAAF: LAAF triggers are often tied to import admissibility, import alert removal, or FDA‑directed testing—and those issues can arise when FDA views a product as violative.
The controlling regulatory section is 21 CFR 1.1107 (When must food testing be conducted under this subpart?): https://www.law.cornell.edu/cfr/text/21/1.1107
Under 21 CFR 1.1107(b), when food testing is conducted under 1.1107(a), sample analysis must be performed by a LAAF‑accredited laboratory for the appropriate analytical method.
LAAF‑mandatory situations are best understood as two buckets:
The LAAF rule includes import‑related testing circumstances, including:
FDA is implementing this category analyte‑by‑analyte. The operational mechanism is:
Primary sources
Based on FDA’s capacity determinations and dashboard postings:
Mycotoxins: FDA announced sufficient capacity and set a compliance date of December 1, 2024 for covered import‑related mycotoxin analyses.
FDA constituent update: https://www.fda.gov/food/hfp-constituent-updates/fda-announces-sufficient-capacity-test-mycotoxins-under-fsma-laboratory-accreditation-analyses-foods
Federal Register notice (June 3, 2024): https://www.federalregister.gov/documents/2024/06/03/2024-12027/laboratory-accreditation-for-analyses-of-foods-program-implementation-determination-of-sufficient
“Next analytes” in 2025: FDA indicated on its dashboard that additional import‑related analytes would be added as capacity becomes sufficient. Industry accreditation bodies publicly reported that FDA determined sufficient capacity for certain melamine and Listeria testing groups as of June 2, 2025, with a reported compliance date of December 2, 2025. Because compliance dates are governed by the dashboard and Federal Register implementation steps, businesses should verify the current analytes and dates on the official dashboard.
Start with the official dashboard: https://datadashboard.fda.gov/oii/fd/laaf.htm
If an ingestible hemp product (or an ingredient used in it) is detained or on an import alert and the pathway to release requires certain analyses (for example, mycotoxins for certain commodities), then covered tests may require a LAAF‑accredited lab—but only for the analytes and circumstances that FDA has activated (via the dashboard and notices).
Also note the timing constraint in 21 CFR 1.1107(c): for import testing under 1.1107(a)(4) or (a)(5), testing generally may occur only after the article arrives in the United States unless FDA provides written approval for pre‑arrival sampling.
The LAAF final rule created a tool called a directed food laboratory order, allowing FDA to require that certain food testing be conducted under the LAAF framework in specific circumstances.
FDA itself has described this tool as intended for rare situations to address an identified or suspected food safety problem.
For ingestible hemp businesses, the takeaway is not that FDA will routinely order LAAF testing—but that when FDA does invoke this authority, your normal vendor testing program may not be sufficient. You would need to pivot quickly to a LAAF‑accredited lab with the exact scope needed.
If you are not in a covered LAAF circumstance, you can still choose to require LAAF‑accredited testing by contract. This is increasingly common for:
Key point: LAAF is not the same as “higher quality,” universally. It is a specific FDA program with additional oversight and reporting expectations in certain contexts. But it can be a strong risk‑reduction signal in procurement.
Many labs will advertise ISO/IEC 17025 accreditation, and for routine quality programs that is a major baseline. But LAAF sits on top of ISO/IEC 17025.
At a high level, LAAF participation involves:
This matters when your business is using results to overcome detention or support admission/removal actions.
Do not rely solely on a logo on a COA. Use the FDA public registry.
For ordinary commercial quality control, an ISO/IEC 17025 lab may be sufficient. But if your shipment is detained and FDA requires evidence to overcome the appearance of a violation in a way that falls under LAAF—then non‑LAAF testing may not satisfy the covered testing requirement.
LAAF is most likely to appear for hemp edible businesses through these paths:
FDA can detain shipments and issue refusal of admission. FDA’s import refusal overview (process‑level): https://www.fda.gov/industry/fda-import-process/import-refusals
If your product is detained, you may attempt to submit evidence to overcome the appearance of a violation. FDA’s “Private Laboratory Testing” resource explains how private lab reports may be used in import alert contexts and provides import alert resources: https://www.fda.gov/science-research/field-science-and-laboratories/private-laboratory-testing
Once an import‑related testing circumstance is “turned on” for an analyte group, the LAAF requirement can become a gating issue: you might have data, but it may not be from an appropriately LAAF‑accredited lab.
Import alerts can trigger Detention Without Physical Examination (DWPE). FDA explains import alerts and their lists (red/yellow/green): https://www.fda.gov/industry/actions-enforcement/import-alerts
If your firm is trying to get product removed from an import alert via consecutive passing shipments, and that pathway involves covered testing under 21 CFR 1.1107(a)(5), LAAF may apply for the activated analytes.
Use the following practical logic when evaluating ingestible hemp products:
If yes, LAAF is usually optional. Focus on:
If yes, ask:
If any of those are true, check the LAAF Dashboard for analyte groups and compliance dates and plan for LAAF testing when required.
Examples include:
Even if LAAF is not mandatory today, you may choose to require it contractually for high‑risk SKUs so you can act quickly during an import event.
Businesses can reduce disruption by embedding LAAF readiness into supplier agreements.
When testing is conducted under the LAAF rule, the laboratory has structured reporting obligations to FDA.
A useful starting point is 21 CFR 1.1152, which details requirements for submitting results and analytical reports directly to FDA: https://www.law.cornell.edu/cfr/text/21/1.1152
Even if your company does not submit the report, you should be prepared for:
From a business continuity perspective, the most important point is that LAAF contexts can be slower and more document‑heavy than routine COA workflows—another reason to plan ahead.
If you’re building a defensible compliance program for ingestible hemp products—especially with imported ingredients—use https://cannabisregulations.ai/ to track regulatory updates, build testing and documentation SOPs, and pressure‑test your procurement language so you’re prepared when FDA import or enforcement issues trigger LAAF‑accredited testing requirements.
